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About one hundred European cardiologists discussed the
role of calcium antagonists in the follow-up management of
myocardial infarction. /?-blockers are the treatment of
choice. Where these are contra-indicated or otherwise un-
suitable, many clinicians would use a non-dihydropyridine
calcium antagonist alone or in combination with an ACE
inhibitor. There is broad agreement that calcium antagon-
ists should not be used in patients with concomitant left
ventricular failure. Cholesterol estimation in post-infarction
patients is essential.
(Eur Heart J 1997; 18 (Suppl A): A134-A138)
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Introduction
Acute myocardial infarction is a spectrum of events
ranging from the early phase, soon after the onset of
chest pain, through to the late post-infarction phase.
There have been few studies of calcium antagonists in
the acute phase so there is little evidence that they are of
benefit. It is therefore not surprising that only 8% of the
participants in the interactive groups were interested
in using these agents in the acute early phase of myo-
cardial infarction; 43%, however, would consider using
a calcium antagonist after the patient had left the
coronary care unit and was in a general ward, or had left
hospital and was being followed-up by a physician or
cardiologist.
Choice of agent
When it came to the choice of calcium antagonists, the
vast majority of participants would use one of the non-
dihydropyridines. Only 5% would use a dihydropyridine
in a patient who had had a myocardial infarction.
Professor Opie suggested that dihydropyridines might be
useful on occasion even though no trial data existed to
support their use. The only study (SPRINT1121) had
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shown no advantage for secondary prevention but the
nifedipine used in the study had been the short-acting
form which clinicians would not consider using today.
One concern participants expressed about the
long-acting dihydropyridines was that the existing
data suggest that they fail to reduce the plasma
catecholamine level and may even increase it.
Beta-blockade
Ninety percent of the participants thought that beta-
blockade should be used in patients who had had a
myocardial infarction. European cardiologists have
clearly been impressed by the weight of evidence that
beta-blockade has a protective effect.
Twenty to 30% of patients have contra-
indications to beta-blockers yet, of those who could take
the drug, only 50% actually receive it. Clinicians may
hesitate to use beta-blockers because patients, particu-
larly elderly ones, complain of tiredness, depression,
sleeping problems and reduced capacity for exercise. It is
therefore important to look at other methods of second-
ary prophylaxis. In Denmark, verapamil has become a
drug of first choice'41.
ACE inhibitors
When beta-blockade was contra-indicated, in patients
with respiratory problems or diabetes, for instance,
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about 50% of participants would use a non-
dihydropyridine calcium antagonist and 31% a combi-
nation of a non-dihydropyridine calcium antagonist and
an ACE inhibitor.
This was an interesting response because there is
no real evidence that ACE inhibitors work as secondary
prophylaxis in patients without heart failure though
there are some signs that they might. They may have
long-term effects by endothelial protection, and perhaps
by the production of bradykinin, but they should not be
considered as first choice for secondary prevention.
For those who choose a non-dihydropyridine,
the evidence of effectiveness is strongest for verapamil
though both verapamil and diltiazem are contra-
indicated in heart failure.
In deciding between a calcium antagonist alone
or in combination with an ACE inhibitor, the actual
evidence favours the calcium antagonist but indirect
data favour the combination. One attraction of the
combination is that the drugs interact with different
mechanisms and the clinician may be able to use a lower
dose of each drug. In the end the decision is a matter of
judgement. There are no hard data defining the 'right'
way to manage these patients.
Secondary prevention
In the later post-MI stages, when the question of
secondary prevention arises, the choice of treatment
depends on whether the patient shows evidence of heart
failure. For patients who were not in heart failure, the
interactive groups agreed that the choice of drug to
achieve secondary prophylaxis lay between a beta-
blocker and a non-dihydropyridine calcium antagonist.
The choice could be based on the expected tolerance
and side-effects of a particular drug, or the doctor's
familiarity with its use.
Patients with heart failure
It was less easy to achieve agreement about the treat-
ment of patients with left ventricular failure though the
vast majority of participants agreed that, on present
evidence, calcium antagonists should not be used.
Faced with a patient with angina and left ven-
tricular systolic dysfunction (ejection fraction <30%),
31% of participants would use an ACE inhibitor and
45% an ACE inhibitor in combination with beta-
blockade. The reasoning behind this choice was that
though the ACE inhibitor would have no direct effect on
the angina, it could act indirectly. It would allow the left
ventricle to maintain an optimal size and shape, reduce
oxygen demand and decrease sympathetic release during
exercise. It was also suggested that there was reasonable,
if not perfect evidence that beta-blockade can be used in
these circumstances.
Thirty-five percent of participants thought beta-
blockade was contra-indicated because of evidence of
deleterious effects on patients with systolic dysfunction
and overt heart failure. They pointed out that beta-
blockade is still an investigative treatment in these
patients. This opinion is shared by the American College
of Cardiology which has recently issued a statement that
the use of beta-blockade in congestive heart failure is
still under evaluation.
The majority of participants felt, however, that
there probably was a case for using beta-blockade in the
post-infarction stage, though not as sole therapy. They
were impressed by the evidence that beta-blockade in
carefully given built-up doses may benefit left ventricular
failure.
In the discussion, Professor Liischer pointed out
that the patient had a poor prognosis so there was a
need not just to treat his symptoms but also to improve
his prognosis. ACE inhibitors would do this. For help
with his angina, the only option Liischer would consider
was beta-blockade, which might also improve the prog-
nosis. The data in support of beta-blockade were not as
solid in patients with an ejection fraction below 30%
as they were for those with values above that level.
Professor Liischer would, however, favour treating this
patient with a combination of ACE inhibitor and beta-
blocker.
Dr Fischer Hansen said there was no real evi-
dence to support the choices the participants had made.
In his unit they would use an ACE inhibitor'3' and
long-acting nitrates. If that was not effective they might
consider using verapamil or a beta-blocker, though he
hesitates to give these drugs in patients with poor
ventricular function because of the lack of evidence that
they offer any benefit to the patient.
Diabetes and dyslipidaemia
The case reports included patients who were diabetic,
or had a high level of circulating lipids. In those circum-
stances most of the participants preferred verapamil to a
/?-blocker, particularly because there is some evidence
that verapamil can assist blood glucose control. There is
no such evidence for beta-blockers. These drugs may
even worsen blood glucose control.
After discussion, all participants agreed that
estimation of the blood cholesterol level was an essential
investigation in the post-infarction period, and that even
in patients with only a moderate degree of lipid elev-
ation, there should be a vigorous attack on cholesterol
levels.
This consensus decision reflects the way in which
the attitude to cholesterol in secondary prevention has
undergone a radical revision. The controversy is clearly
over. The evidence now available suggests that in
patients with signs of atherosclerosis who have had an
infarction, the estimation of cholesterol is mandatory.
The level of cholesterol that determines intervention
should be set quite low.
Diet and weight control should be used but
this group of patients who require not primary but
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Figure 1 Drug therapy in post-MI patients classified
using left ventricular ejection fraction. Adapted from
J. Fischer Hansen
Figure 2 Drug therapy in post-patients classified due to
clinical findings of CHF in the acute phase of MI.
Adapted from J. Fischer Hansen
secondary prevention, need early intervention with drug
therapy.
Possible protocols
When classifying patients who have had a myocardial
infarction, it is possible to do so in a way that helps
determine the type of secondary prevention that should
be used. One way of classification (Fig. 1) is to use
echocardiography. A left ventricular ejection fraction
below 35% is a clear indication for secondary prevention
with an ACE inhibitor.
There is less certain information about treatment
with /?-blockers or with verapamil. The data available
suggest that verapamil should be used only in patients
with normal or slightly depressed systolic function.
/?-blockers may be used over a wider range.
Another method of classification is to consider
clinical findings during the acute stage of infarction, as
was done in the AIRE study'31 and DAVIT II[4]. Patients
were then divided into those with and without clinical
findings of congestive heart failure (Fig. 2). The AIRE
study demonstrated that if patients had had congestive
heart failure while in the coronary care unit, they
Figure 3 Drug therapy in post-MI patients classified due
to CHF and therapy with diuretics in the CCU. Adapted
from J. Fischer Hansen
benefited from an ACE inhibitor. DAVIT II showed
that verapamil benefited those without heart failure or
slightly depressed systolic function.
A third way of classification (Fig. 3) is based on
whether the patients had heart failure in the coronary
care unit and whether they were still receiving diuretics.
Dr Fischer Hansen suggested that a simple, practical
approach to the management of patients in the post-
infarction stage is to ask: 'Does this patient need a
diuretic?' If the answer is 'yes', he or she should be given
an ACE inhibitor. If the answer is 'no', secondary
prevention should be provided with an anti-ischaemic
drug. Dr Fischer Hansen favours verapamil, but a
beta-blocker could also be used.
All patients need cholesterol control. All of them
should also receive aspirin except those who have atrial
fibrillation in which case coumarin offers better protec-
tion. Low blood flow in a large atrium may encourage
fibrin-dependent thrombus formation. Trials in atrial
fibrillation suggest that coumarin is superior to aspirin
for this particular indication.
The authors would like to acknowledge the assistance of Dr
Michael O'Donnell and Paul Castle in the preparation of the
manuscript.
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Case 1
Male, 76 years
Present history:
Patient admitted directly to CCU with chest
discomfort, sweating, chills, and general
malaise of sudden onset beginning 1 hr before
admission
Previous history:
Systemic hypertension for 20 years
Rare episodes of chest discomfort with exercise
Episodes of podagra/gout
Cigarettes 5/day for 60 years
Treatment before admission:
Metoprolol: 50 mg/day
Hydrochlorothiazide:
Amiloride:
Prazosine:
50 mg/day
5 mg/day
5 mg/day
Status:
No dyspnoea
No signs of congestive heart failure
Blood pressure: 180/120 mmHg
Heart rate: 48 bpm
Acute treatment:
APSAC, heparine, aspirin, morphine,
oxygen
Uncomplicated cause
What should you know or examine ?
100
Exercise test
Load Heart rate
Rest
50 Watt
100 Watt
125 Watt
58
95
118
129
Rate pressure product:
Rest
Maximal
Maximal/Rest =
8700
30960
3.5
Systolic BP
150
190
240
240
Echocardiogram
Left ventricle:
Which treatment would you administer
at discharge ?
100
Diameter in diastole:
Diameter in systole:
Posterior wall thickness:
Septum thickness:
Wall motion index:
Left atrial diameter:
44 mm
33 mm
20 mm
16 mm
1.7 (EF = 50%)
48 mm
80
60
40
20
0
_77%
27%
10%
Aspirin Beta- Nifedipine Diltiazem Verapamil Diuretics
blocker
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Regarding AMI, in which phase of AMI
do you think calcium antagonists could
be used ?
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Should beta-blockade be used post-MI ?
Yes Sometimes
Do you think there are differences between
calcium antagonists in relation to
post-MI use ?
80
60
40
20
• H 98%
•I
•
1%
Yes No Sometimes
If beta-blockade is contraindicated
(respiratory problems, diabetes),
which drug(s) would you use ?
Which drugs are contraindicated in the
presence of systolic heart failure and
clinical symptoms ?
100
Beta- ApE- Verapamil None of the
blocker inhibitor above
In post-MI patients with LV systolic
dysfunction (i.e. depressed LV ejection
fraction <30%) and angina, which
of the following drugs is indicated ?
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